Core Curriculum 2017

Question 1

What are the three metals used for brachytherapy?

Answer 1

Iodine-125, Palladium-103 and Iridium-192

Question 2

What are relative contraindications to radiation?

Answer 2

Prostate > 60 g, TURP, IPSS > 15

Question 3

What 3 trials show benefit of adjuvant radiation to prostate bed after radical prostatectomy?

Answer 3

EORTC 22911
ARO 9602
SWOG 8794

Question 4

What did SWOG 8794 show?

Answer 4

Adjuvant XRT improved OS compared to salvage. This was attributable to the number of patients with detectable PSA upon adjuvant treatment

Question 5

What did EORTC 22911 and ARO 9602 show?

Answer 5

improvement in bRFS but not OS or DMFS

Question 6

Which patients are likely to benefit from salvage XRT?

Answer 6

Gl < 7
pre-RT PSA < 2
neg SVI
(+) margins
PSA doubling time > 10 mo

Question 7

One in __ men will be diagnosed with prostate cancer during their lifetime.

Answer 7

7

Question 8

What percentage of men will die from prostate cancer?

Answer 8

2.8%

Question 9

What ages does AUA recommend offering CaP screening?

Answer 9

55-69

Question 10

What life expectancy should you stop offering screening?

Answer 10

10-15 year life expectancy

Question 11

The European Randomized Study of Screening for Prostate cancer reported what?

Answer 11

A statistically significant relative reduction of 21% in prostate cancer mortality at 11 years.

Question 12

What is very low risk prostate cancer per NCCN

Answer 12

PSA ≤ 10 ng/mL, Gleason score ≤ 6, clinical stage T1c, < 3 positive biopsy cores, ≤ 50% in each core, and PSA density < 0.15 ng/mL/g

Question 13

Per NCCN, define low risk prostate cancer

Answer 13

PSA < 10 ng/mL, Gleason score ≤ 6, and clinical stageT1-T2a

Question 14

Per NCCN, define intermediate risk prostate cancer

Answer 14

PSA 10 - 20, Gleason score ≤ 7, and clinical stage T2b-c

Question 15

Per NCCN, define high risk prostate cancer

Answer 15

PSA > 20, Gl 8-10, cT3a

Question 16

Per NCCN, define very high risk prostate cancer

Answer 16

cT3b - T4

Question 17

Define AUA low risk prostate cancer

Answer 17

PSA ≤ 10 ng/mL, Gleason score ≤ 6, clinical stage T1c or cT2a

Question 18

Define AUA intermediate risk prostate cancer

Answer 18

PSA > 10-20 ng/mL or Gleason score 7, or clinical stage T2b

Question 19

Define AUA high risk prostate cancer

Answer 19

PSA > 20 or Gleason score 8-10, or clinical stage ≥T2c

Question 20

What did the prostate cancer prevention trial show and in what patients?

Answer 20

in men with low risk of disease, PSA < 3, finasteride decreased overall relative risk of CaP by 25%

Question 21

What did the REDUCE trial show and on which patients?

Answer 21

men with PSA 2.5 to 10 & prior neg biopsy on dutasteride had a relative risk reduction of 25% and absolute risk reduction of 5% of prostate cancer

Question 22

Why did the FDA refuse to issue an indication for CaP chemoprevention with 5ARI?

Answer 22

risk of high grade cancer may be higher in those patients

Question 23

What did the SELECT trial show?

Answer 23

selenium and vitamin E made no difference in the rate of prostate cancer

Question 24

What did SPCG4 show? Scandinavian prostate cancer group study #4

Answer 24

improvement in overall and disease specific mortality in men undergoing radical prostatectomy

Question 25

PIVOT trial found what?

Answer 25

Radical prostatectomy did not improve OS or DSM but did reduce risk of mets with >= Gl 7